# Program 1 Architecture Review Track Phase A - Synthetic-Only Pre-Implementation Architecture Boundary

Status: documentation-only, synthetic-only, non-production, non-runtime, pre-implementation architecture boundary. Not an implementation authorization.

## Purpose

Program 1 Architecture Review Track Phase A defines permitted and prohibited boundaries for any possible future Program 1 implementation discussion. It starts after the governance/prototype sequence closed through Phase Z. It is not Phase Z+1.

Program 1 remains in pre-implementation hold.

## Track transition

The Phase V-Z governance/prototype sequence is closed. Phase Z placed Program 1 into pre-implementation hold. A separate Architecture Review Track is created instead of continuing with Phase Z+1 because the next safe activity is architecture boundary clarification before any future implementation discussion.

This track does not reopen the prior governance/prototype sequence and does not authorize runtime implementation.

## Scope

- Synthetic-only architecture boundaries.
- Conceptual module separation.
- Conceptual read-only vs write-capable boundaries.
- Conceptual data classification preview.
- Conceptual human-in-the-loop responsibility preview.
- Future approval dependency mapping.
- Prohibited runtime path register.

## Non-scope

Phase A does not add runtime code, tests, helpers, scripts, imports, services, migrations, endpoints, UI flows, schedulers, task runners, integrations, runtime auth/authz/RBAC, runtime audit logging, patient messaging, appointment mutation, workflow enforcement, Task engine, Outcome Evidence, clinical write workflows, approval/clearance/override runtime capability, production-readiness claim, or go-live authorization.

## Safety boundaries

Phase A does not approve production use, real patient data, PHI/PII processing, live clinical deployment, clinical validation, operational clearance, go-live, runtime implementation, or approval/clearance/override behavior.

## Synthetic-only architecture boundary

Architecture discussion in this track may use only synthetic examples, abstract entities, non-patient data, non-PHI placeholders, non-PII placeholders, and documentation diagrams or text-only models.

Real patient data, live clinic data, identifiable patient examples, imported production datasets, real appointment records, real messages, real clinical documents, and real audit events remain prohibited.

## Permitted discussion areas

Permitted discussion areas are architecture boundaries, module separation, synthetic data flow diagrams, read-only vs write-capable conceptual boundaries, data classification models, clinical responsibility models, human-in-the-loop review concepts, security architecture concepts, audit model concepts, authorization model concepts, future dependency maps, and prohibited path registers.

## Prohibited runtime paths

Current creation of production data ingestion, patient profile mutation, appointment status mutation, patient messaging, clinical notes writing, diagnosis writing, treatment recommendation execution, task creation or assignment, Outcome Evidence creation, workflow enforcement, approval/clearance/override execution, audit logging runtime capture, RBAC runtime enforcement, and deployment automation is prohibited.

## Data classification preview

Phase A allows only synthetic data and abstract placeholders. All real, identifiable, PHI/PII, production, or clinic-derived data remains prohibited.

## Read-only vs write-capable boundary

Phase A does not authorize read-only runtime access. Phase A does not authorize write-capable runtime behavior. Phase A only documents conceptual boundaries.

## Human-in-the-loop responsibility preview

Any future clinical use concept would require accountable licensed clinician responsibility, explicit human review, no autonomous diagnosis, no autonomous treatment, no automatic patient instruction, no automatic workflow enforcement, and no automatic appointment mutation. This is a future review concept only, not an implemented model.

## Future approval dependency map

Future implementation consideration would require explicit authorization to leave pre-implementation hold, production governance review, privacy/legal review for PHI/PII, clinical safety review, clinical accountability model, security architecture review, authorization architecture review, audit architecture review, incident response model, rollback model, validation evidence model, and deployment governance model.

## Explicit non-approval statement

This phase is not production approved, not implementation approved, not clinically validated, not real-data ready, not cleared for PHI/PII, not operationally approved, not go-live ready, and not runtime approved.

## Next-step decision

Recommended next step: `Program 1 Architecture Review Track Phase B - Synthetic Architecture Component Inventory`, documentation-only unless explicitly authorized otherwise.

## Closure statement

Architecture Review Track Phase A closes with Program 1 still in pre-implementation hold and all runtime, production, real-data, PHI/PII, clinical workflow, approval/clearance/override, and go-live boundaries active.
